Eon Labs First to Commercialize Generic Fluvoxamine Maleate Tablets.

Business Editors/Health & Medical Writers

LAURELTON, N.Y.--(BW HealthWire)--Dec. 15, 2000

Eon Labs has received approval from the U.S. Food and Drug Administration to market Fluvoxamine Maleate 25mg, 50mg and 100mg Tablets. Eon is the first manufacturer to commercialize generic Fluvoxamine Maleate Tablets, the low cost alternative to the brand Luvox(R)(a). Sales of the Obsessive Compulsive Disorder treatment jumped by 17% in the past 12 months as demand has increased. Luvox(R) generated sales of nearly $200 million in over the same period.

"Fluvoxamine Maleate Tablets is the 14th approval granted to Eon Labs in the year 2000, and our fourth `first to market' of the year," said Frank Della Fera, Vice President of Sales and Marketing for Eon Labs. "Eon Labs is not only a leader in approvals, but in timely generic introductions. We are dedicated to providing a steady stream of high quality new generics to our customers," concluded Della Fera.

Eon Labs is one of the leading generic pharmaceutical companies in the U.S., widely known as the "Pharmacy Drug Company." For more information on Eon Fluvoxamine Maleate Tablets, 25mg, 50mg, and 100mg, or other quality product from Eon Labs, call 800/526-0225, or write to Eon Labs Manufacturing, Inc., 227-15 N. Conduit Avenue, Laurelton, N.Y., 11413.

Note: (a)Lavox is a registered trademark of Solvay Pharmaceuticals, Inc. and is not affiliated with Eon Labs Manufacturing, Inc.